Negative regulatory NLRs mitigate inflammation via NF-κB pathway signaling in inflammatory bowel disease
Biomedical Journal · 2023
DOI: 10.1016/j.bj.2023.100616 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Journal, 2023. Verfasst von Holly A Morrison und 3 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Tech, Virginia Maryland College of Veterinary Medicine, Department of Biomedical Science and Pathobiology, Blacksburg VA, USA. Hauptthemen laut MEDLINE: Colitis-Associated Neoplasms, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A subset of Nucleotide-binding and leucine-rich repeat-containing receptors (NLRs) function to mitigate overzealous pro-inflammatory signaling produced by NF-κB activation. Under normal pathophysiologic conditions, proper signaling by these NLRs protect against potential autoimmune responses. These NLRs associate with several different proteins within both the canonical and noncanonical NF-κB signaling pathways to either prevent activation of the pathway or inhibit signal transduction. Inhibition of the NF-κB pathways ultimately dampens the production of pro-inflammatory cytokines and activation of other downstream pro-inflammatory signaling mechanisms. Dysregulation of these NLRs, including NLRC3, NLRX1, and NLRP12, have been reported in human inflammatory bowel disease (IBD) and colorectal cancer patients, suggesting the potential of these NLRs as biomarkers for disease detection. Mouse models deficient in these NLRs also have increased susceptibility to colitis and colitis-associated colorectal cancer. While current standard of care for IBD patients and FDA-approved therapeutics function to remedy symptoms associated with IBD and chronic inflammation, these negative regulatory NLRs have yet to be explored as potential drug targets. In this review, we describe a comprehensive overview of recent studies that have evaluated the role of NLRC3, NLRX1, and NLRP12 in IBD and colitis-associated colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Virginia Tech, Virginia Maryland College of Veterinary Medicine, Department of Biomedical Science and Pathobiology, Blacksburg VA, USA.
- Virginia Tech, Virginia Maryland College of Veterinary Medicine, Department of Biomedical Science and Pathobiology, Blacksburg VA, USA; Virginia Tech, Department of Basic Science Education, Virginia Tech Carilion School…
Zitieren
APA
Morrison, H. A., Trusiano, B., Rowe, A. J., & Allen, I. C. (2023). Negative regulatory NLRs mitigate inflammation via NF-κB pathway signaling in inflammatory bowel disease. Biomedical Journal. https://doi.org/10.1016/j.bj.2023.100616
Vancouver
Morrison HA, Trusiano B, Rowe AJ, Allen IC. Negative regulatory NLRs mitigate inflammation via NF-κB pathway signaling in inflammatory bowel disease. Biomedical Journal. 2023. doi:10.1016/j.bj.2023.100616
BibTeX
@article{Morrison2023,
author = {Morrison, Holly A and Trusiano, Brie and Rowe, Audrey J and Allen, Irving C},
title = {Negative regulatory NLRs mitigate inflammation via NF-κB pathway signaling in inflammatory bowel disease},
journal = {Biomedical Journal},
year = {2023},
doi = {10.1016/j.bj.2023.100616}
}
EUVIMED